© 2000 American Heart Association, Inc.
Brief Review |
Thrombin Activatable Fibrinolysis Inhibitor and an Antifibrinolytic Pathway
From the Hamilton Civic Hospitals Research Centre and McMaster University, Hamilton, Ontario, Canada.
Correspondence to Laszlo Bajzar, PhD, HCHRC, 711 Concession St, Hamilton, ON, Canada L8V 1C3. E-mail lbajzar{at}thrombosis.hhscr.org
Abstract—Coagulation and fibrinolysis are processes that form and dissolve fibrin, respectively. These processes are exquisitely regulated and protect the organism from excessive blood loss or excessive fibrin deposition. Regulation of these cascades is accomplished by a variety of mechanisms involving cellular responses, flow, and protein-protein interactions. With respect to regulation mediated by protein-protein interaction, the coagulation cascade appears to be more complex than the fibrinolytic cascade because it has more components. Yet each cascade is regulated by initiators, cofactors, feedback reactions, and inhibitors. Coagulation is also controlled by an anticoagulant pathway composed of (minimally) thrombin, thrombomodulin, and protein C.1 Protein C is converted by the thrombin/thrombomodulin complex to activated protein C (APC), which catalyzes the proteolytic inactivation of the essential cofactors required for thrombin formation, factors Va and VIIIa. An analogous antifibrinolytic pathway has been identified recently. This pathway provides an apparent symmetry between coagulation and fibrinolysis and is also composed of thrombin, thrombomodulin, and a zymogen that is activated to an enzyme. The enzyme proteolytically inactivates a cofactor to attenuate fibrinolysis. However, unlike APC, which is a serine protease, the antifibrinolytic enzyme is a metalloprotease that exhibits carboxypeptidase B–like activity. Within a few years of each other, 5 groups independently described a molecule that accounts for this antifibrinolytic activity. We refer to this molecule as thrombin activatable fibrinolysis inhibitor (TAFI), a name that is based on functional properties by which it was identified, assayed, and purified. (Because of the preferences of some journals "activatable" is occasionally referred to as "activable.") This review will encompass a historical account of efforts to isolate TAFI and characterize it with respect to its activation, activity, regulation, and potential function in vivo.
Key Words: coagulation • fibrinolysis • thrombosis • thrombolysis • risk factors
This article has been cited by other articles:
 |
|
 |
|
  N. Okumura, T. Koh, Y. Hasebe, T. Seki, and T. Ariga A Novel Function of Thrombin-activatable Fibrinolysis Inhibitor during Rat Liver Regeneration and in Growth-promoted Hepatocytes in Primary Culture J. Biol. Chem., June 12, 2009; 284(24): 16553 - 16561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Biscetti Glycosylation of Thrombin Activatable Fibrinolysis Inhibitor: Why Is it So Important? Circ. Res., February 15, 2008; 102(3): 278 - 279. [Full Text] [PDF]
|
|
|
|
|
|
M.-C. Bouton, L. Venisse, B. Richard, C. Pouzet, V. Arocas, and M. Jandrot-Perrus Protease Nexin-1 Interacts With Thrombomodulin and Modulates Its Anticoagulant Effect Circ. Res., April 27, 2007; 100(8): 1174 - 1181. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Fujimoto, E. C. Gabazza, O. Taguchi, Y. Nishii, H. Nakahara, N. E. Bruno, C. N. D'Alessandro-Gabazza, M. Kasper, Y. Yano, M. Nagashima, et al. Thrombin-Activatable Fibrinolysis Inhibitor Deficiency Attenuates Bleomycin-Induced Lung Fibrosis Am. J. Pathol., April 1, 2006; 168(4): 1086 - 1096. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Kaftan, O. S. Balcik, H. Cipil, G. Ozet, N. Bavbek, A. Kosar, and S. Dagdas Plasma Levels of Thrombin-Activatable Fibrinolysis Inhibitor in Primary and Secondary Thrombocytosis Clinical and Applied Thrombosis/Hemostasis, October 1, 2005; 11(4): 449 - 454. [Abstract] [PDF]
|
|
|
|
 |
|
 Y. Aso, S. Wakabayashi, R. Yamamoto, R. Matsutomo, K. Takebayashi, and T. Inukai Metabolic Syndrome Accompanied by Hypercholesterolemia Is Strongly Associated With Proinflammatory State and Impairment of Fibrinolysis in Patients With Type 2 Diabetes: Synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor Diabetes Care, September 1, 2005; 28(9): 2211 - 2216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Marti-Fabregas, M. Borrell, D. Cocho, R. Belvis, M. Castellanos, J. Montaner, J. Pagonabarraga, A. Aleu, L. Molina-Porcel, J. Diaz-Manera, et al. Hemostatic markers of recanalization in patients with ischemic stroke treated with rt-PA Neurology, August 9, 2005; 65(3): 366 - 370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N Assy, S Schlesinger, and O Hussein Elevated plasma protein C levels correlate with the presence of fatty liver (NASH and NAFLD) Gut, May 1, 2005; 54(5): 729 - 729. [Full Text] [PDF]
|
|
|
|
|
|
T. M. Ravindranath, M. Goto, M. Demir, M. Tobu, M. F. Kujawski, D. Hoppensteadt, V. Samonte, O. Iqbal, M. M. Sayeed, and J. Fareed Tissue Factor Pathway Inhibitor and Thrombin Activatable Fibrinolytic Inhibitor Plasma Levels following Burnand Septic Injuries in Rats Clinical and Applied Thrombosis/Hemostasis, October 1, 2004; 10(4): 379 - 385. [Abstract] [PDF]
|
|
|
|
 |
|
 J.-M. Olivot, J. Labreuche, M. Aiach, P. Amarenco, and for the GENIC Investigators Soluble Thrombomodulin and Brain Infarction: Case-Control and Prospective Study Stroke, August 1, 2004; 35(8): 1946 - 1951. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Eichinger, V. Schonauer, A. Weltermann, E. Minar, C. Bialonczyk, M. Hirschl, B. Schneider, P. Quehenberger, and P. A. Kyrle Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism Blood, May 15, 2004; 103(10): 3773 - 3776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Suzuki, Y. Muto, K. Fushihara, K.-i. Kanemoto, H. Iida, E. Sato, C. Kikuchi, T. Matsushima, E. Kato, M. Nomoto, et al. J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 607 - 615. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hertig and E. Rondeau Role of the Coagulation/Fibrinolysis System in Fibrin-Associated Glomerular Injury J. Am. Soc. Nephrol., April 1, 2004; 15(4): 844 - 853. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Colucci, B. M. Binetti, A. Tripodi, V. Chantarangkul, and N. Semeraro Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism Blood, March 15, 2004; 103(6): 2157 - 2161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yano, E. C. Gabazza, N. Kitagawa, N. E. Bruno, K. Matsumoto, K. Nakatani, R. Araki, A. Katsuki, Y. Adachi, and Y. Sumida Tumor Necrosis Factor-{alpha} Is Associated With Increased Protein C Activation in Nonobese Type 2 Diabetic Patients Diabetes Care, March 1, 2004; 27(3): 844 - 845. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Barton, A. C. Kalil, S. Nadel, B. Goldstein, R. Okhuysen-Cawley, R. J. Brilli, J. S. Takano, L. D. Martin, P. Quint, T. S. Yeh, et al. Safety, Pharmacokinetics, and Pharmacodynamics of Drotrecogin Alfa (Activated) in Children With Severe Sepsis Pediatrics, January 1, 2004; 113(1): 7 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Camerer, D. N. Duong, J. R. Hamilton, and S. R. Coughlin Combined deficiency of protease-activated receptor-4 and fibrinogen recapitulates the hemostatic defect but not the embryonic lethality of prothrombin deficiency Blood, January 1, 2004; 103(1): 152 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Myles, T. Nishimura, T. H. Yun, M. Nagashima, J. Morser, A. J. Patterson, R. G. Pearl, and L. L. K. Leung Thrombin Activatable Fibrinolysis Inhibitor, a Potential Regulator of Vascular Inflammation J. Biol. Chem., December 19, 2003; 278(51): 51059 - 51067. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Dettenmeier, B. Swindell, M. Stroud, N. Arkins, and A. Howard Role of Activated Protein C in the Pathophysiology of Severe Sepsis Am. J. Crit. Care., November 1, 2003; 12(6): 518 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Santamaria, A. Oliver, M. Borrell, J. Mateo, R. Belvis, J. Marti-Fabregas, R. Ortin;, I. Tirado, J.C. Souto, and J. Fontcuberta Risk of Ischemic Stroke Associated With Functional Thrombin-Activatable Fibrinolysis Inhibitor Plasma Levels Stroke, October 1, 2003; 34(10): 2387 - 2391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nesheim Thrombin and Fibrinolysis Chest, September 1, 2003; 124 (2009): 33S - 39S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zhao, B. Buckman, M. Seto, J. Morser, and M. Nagashima Mutations in the Substrate Binding Site of Thrombin-activatable Fibrinolysis Inhibitor (TAFI) Alter Its Substrate Specificity J. Biol. Chem., August 22, 2003; 278(34): 32359 - 32366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Lian, S. J. Szarka, K. K. S. Ng, and S.-L. Wong Engineering of a Staphylokinase-based Fibrinolytic Agent with Antithrombotic Activity and Targeting Capability toward Thrombin-rich Fibrin and Plasma Clots J. Biol. Chem., July 11, 2003; 278(29): 26677 - 26686. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Fujimoto, E. C. Gabazza, O. Hataji, H. Yuda, C. N. D'Alessandro-Gabazza, M. Nakano, O. E. Franco, T. Hayashi, K. Suzuki, Y. Adachi, et al. Thrombin-activatable Fibrinolysis Inhibitor and Protein C Inhibitor in Interstitial Lung Disease Am. J. Respir. Crit. Care Med., June 15, 2003; 167(12): 1687 - 1694. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yano, N. Kitagawa, E. C. Gabazza, K. Morioka, H. Urakawa, T. Tanaka, A. Katsuki, R. Araki-Sasaki, Y. Hori, K. Nakatani, et al. Increased Plasma Thrombin-Activatable Fibrinolysis Inhibitor Levels in Normotensive Type 2 Diabetic Patients with Microalbuminuria J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 736 - 741. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yano, E. C. Gabazza, Y. Hori, N. Kitagawa, A. Katsuki, R. Araki-Sasaki, Y. Sumida, and Y. Adachi Association Between Plasma Thrombin-Activatable Fibrinolysis Inhibitor Levels and Activated Protein C in Normotensive Type 2 Diabetic Patients Diabetes Care, July 1, 2002; 25(7): 1245 - 1246. [Full Text] [PDF]
|
|
|
|
|
|
S. Salamanca, V. Villegas, J. Vendrell, L. Li, F. X. Aviles, and J.-Y. Chang The Unfolding Pathway of Leech Carboxypeptidase Inhibitor J. Biol. Chem., May 10, 2002; 277(20): 17538 - 17543. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Juhan-Vague, P.E. Morange, H. Aubert, M. Henry, M.F. Aillaud, M.C. Alessi, A. Samnegard, E. Hawe, J. Yudkin, M. Margaglione, et al. Plasma Thrombin-Activatable Fibrinolysis Inhibitor Antigen Concentration and Genotype in Relation to Myocardial Infarction in the North and South of Europe Arterioscler Thromb Vasc Biol, May 1, 2002; 22(5): 867 - 873. [Abstract] [Full Text] [PDF]
|
|